Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2

Dan Zhao, Weifan Xu, Xiaofan Zhang, Xiaoting Wang, Enming Yuan, Yuanpeng Xiong, Shenyang Wu, Shuya Li, Nian Wu, Tingzhong Tian, Xiaolong Feng, Hantao Shu, Lang Peng, Xiaokun Shen, Haitao Li, Pilong Li, Jianyang ZengbioRxiv 2020 · DOI

TL;DR

This study reveals that the SARS-CoV-2 nucleocapsid (N) protein undergoes liquid-liquid phase separation (LLPS), a process crucial for viral replication. They discovered that the viral RNA polymerase component, nsp12, is recruited into these N protein condensates, and importantly, identified small molecules (CVL218 and PJ34) that can disrupt this process, potentially opening new avenues for antiviral drug development.

What Problem Does This Paper Address?

The COVID-19 pandemic has highlighted the urgent need for effective therapeutics against SARS-CoV-2. While the spike protein and viral enzymes have been targets, success has been limited. The nucleocapsid (N) protein of SARS-CoV-2 plays a vital role in viral RNA packaging and replication. However, the precise mechanisms by which it contributes to these processes, particularly its role in organizing viral machinery within the cell, remained unclear. This paper investigates the biophysical properties of the N protein, specifically its tendency to form liquid-like condensates through liquid-liquid phase separation (LLPS), and how this phenomenon might be exploited for therapeutic intervention.

Methods

The researchers employed a multi-pronged approach:

  • In vitro and in vivo LLPS assays: They used microscopy techniques (confocal fluorescence microscopy, time-lapse imaging) to observe the formation and behavior of N protein condensates in purified protein solutions and in living cells (Vero E6).
  • Fluorescence Recovery After Photobleaching (FRAP): This technique was used to assess the dynamics and fluidity of the internal molecules within the condensates, indicating their liquid-like nature.
  • Bioinformatic analysis: Sequence analysis was performed to identify intrinsically disordered regions (IDRs) and potential prion-like activity within the N protein, which are known to be associated with LLPS.
  • Protein expression and purification: Recombinant N protein and its truncated forms, as well as nsp12, were expressed in E. coli and purified for biochemical experiments.
  • RNA synthesis and labeling: Synthetic viral RNA fragments were created and labeled for use in phase separation experiments.
  • Surface Plasmon Resonance (SPR): This biophysical technique was used to quantify the binding affinity of small molecules (CVL218 and PJ34) to the N protein.
  • Mutagenesis studies: Specific mutations were introduced into the N protein to investigate the role of different domains and regions in LLPS.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • N protein drives LLPS: The SARS-CoV-2 N protein, both in vitro and in vivo, readily forms liquid-like condensates, suggesting a fundamental role in organizing viral components.
  • Viral RNA is a key modulator: The presence of viral RNA significantly enhances and stabilizes these N protein condensates, highlighting the importance of the N-RNA complex.
  • Nsp12 is recruited into N condensates: The core component of the viral RNA-dependent RNA polymerase (RdRp), nsp12, is preferentially drawn into the N protein-RNA condensates, suggesting a physical link between N protein condensation and viral replication machinery.
  • Small molecules can disrupt LLPS: Two small molecules, CVL218 and PJ34, were found to interact with the N protein and, more importantly, to increase the internal mobility and loosen the structure of the N-RNA-nsp12 condensates.
  • LLPS as a therapeutic target: The ability of these small molecules to modulate the biophysical properties of the condensates suggests that targeting N protein LLPS could be a novel strategy for developing antivirals.

Key Results

  • SARS-CoV-2 N protein forms micron-sized spherical condensates in vitro, which exhibit liquid-like properties such as fusion and dynamic internal exchange.
  • In vivo, N protein also forms puncta-like structures in cells, demonstrating LLPS within a cellular environment.
  • The addition of viral RNA leads to more robust and spherical N-RNA condensates.
  • Nsp12 is recruited into these N-RNA condensates, forming a complex that appears to be more solid-state and less dynamic than N-RNA alone.
  • CVL218 and PJ34 bind to the N protein and, when added to N-RNA-nsp12 condensates, increase their internal mobility and size, making them more "liquid-like."
  • Mutations in the serine-arginine (SR) rich region of the N protein significantly impair its LLPS ability.

Limitations and Future Work

  • In vivo relevance of small molecules: While CVL218 and PJ34 showed promise in vitro, their efficacy and mechanism of action in a full viral infection context require further investigation.
  • Mechanism of drug action: The exact mechanism by which CVL218 and PJ34 enhance condensate mobility and potentially improve drug accessibility needs more detailed study.
  • LLPS as a universal mechanism: While LLPS is implicated in viral replication, further research is needed to confirm if it's a common mechanism across all coronaviruses and other viruses.
  • Therapeutic development: The authors propose a conceptual framework for developing combination therapies targeting both N protein and nsp12/RdRp, but this requires extensive preclinical and clinical validation.
  • Role of other nsps: The study focuses on N protein and nsp12; the roles of other non-structural proteins in LLPS and viral replication warrant further exploration.

Summary updated

Abstract

Abstract The ongoing coronavirus disease 2019 (COVID-19) pandemic has raised an urgent need to develop effective therapeutics against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As a potential antiviral drug target, the nucleocapsid (N) protein of SARS-CoV-2 functions as a viral RNA chaperone and plays vital and multifunctional roles during the life cycle of coronavirus 1-3 . In this study, we discovered that the N protein of SARS-CoV-2 undergoes liquid-liquid phase separation (LLPS) both in vitro and in vivo , which is further modulated by viral RNA. In addition, we found that, the core component of the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, nsp12, preferentially partitions into the N protein condensates. Moreover, we revealed that, two small molecules, i.e., CVL218 and PJ34, can be used to intervene the N protein driven phase separation and loosen the compact structures of the condensates of the N-RNA-nsp12 complex of SARS-CoV-2. The discovery of the LLPS-mediated interplay between N protein and nsp12 and the corresponding modulating compounds illuminates a feasible way to improve the accessibility of antiviral drugs (e.g., remdesivir) to their targets (e.g., nsp12/RdRp), and thus may provide useful hints for further development of effective therapeutic strategies against SARS-CoV-2.
BibTeX
@misc{zhao2020understanding,
  author = {Dan Zhao and Weifan Xu and Xiaofan Zhang and Xiaoting Wang and Enming Yuan and Yuanpeng Xiong and Shenyang Wu and Shuya Li and Nian Wu and Tingzhong Tian and Xiaolong Feng and Hantao Shu and Lang Peng and Xiaokun Shen and Haitao Li and Pilong Li and Jianyang Zeng},
  title = {{Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2}},
  year = {2020},
  doi = {10.1101/2020.10.09.332734},
  howpublished = {bioRxiv},
}
Figure